Our germline tests are clinical grade, with fast turnaround times and actionable results. We also have in-house certified genetic counselors to aid in interpretation of results and to provide guidance to patients.
FDA-cleared for use in all solid tumors, OncoTarget®500 harnesses vast genomic data to identify personalized treatment options.
With OncoTracking™, signs of recurrence can be identified sooner than traditional screening tools. OncoTracking™ is a highly sensitive monitoring tool that utilizes liquid biopsy to screen for circulating tumor DNA (ctDNA), which is indicative of cancer recurrence and can be found before the recurrence is detectable on imaging.